Erratum: A novel arsenical has antitumor activity toward As2 O3-resistant and MRP1/ABCC1-overexpressing cell lines (Leukemia (2008) vol. 22 (1853-1863) 10.1038/leu.2008.194);A novel arsenical has antitumor activity toward As2 O3-resistant and MRP1/ABCC1-overexpressing cell lines

Leukemia

Volumn 22, Issue 10, 2008, Pages 1853-1863

  Diaz, Z ^a   Mann, K K ^a   Marcoux, S ^a   Kourelis, M ^a   Colombo, M ^a   Komarnitsky, P B ^b   Miller Jr , W H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Ziopharm Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ARSENIC TRIOXIDE; DARINAPARSIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANOARSENIC DERIVATIVE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; EMBRYO; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 54049154237     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.328     Document Type: Erratum

References (40)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
2. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006; 107: 2627-2632.
3. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134.
4. Niu C, Yan H, Sun HP, Liu JX, Gu BW, Su XY et al. Treatment of de novo and relapsed acute promyelocytic patients with arsenic trioxide. Blood 1998; 92 (Suppl 1): 678a.
5. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
6. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19 3852-3860.
7. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002; 133: 1-16.
8. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W et al Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003; 278: 37832-37839.
9. Zheng Y, Yamaguchi H, Tian C, Lee MW, Tang H, Wang HG et al. Arsenic trioxide (As(2)O(3)) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 2005; 24: 3339-3347.
10. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
11. Lee TC, Wei ML, Chang WJ, Ho IC, Lo JF, Jan KY et al. Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol 1989; 25: 442-448.
12. Ochi T, Kaise T, Oya-Ohta Y. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia 1994; 50 115-120.
13. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17: 931-940.
14. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 2006; 97: 540-545.
15. Davison K, Mann KK, Waxman S, Miller Jr WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004; 103: 3496-3502.
16. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998; 102: 1055-1060.
17. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB et al Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6: 4957-4964.
18. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck Im Y et al. Arsenic trioxide inhibits the growth of A498° renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230-235.
19. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003; 63: 1853-1859.
20. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6 (Suppl 2): 3-10.
21. Camacho LH, Hong D, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA et al. Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers (abstract). J Clin Oncol 2006; 24 (18S): P 605S.
22. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: Nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 2001; 20: 7287-7291.
23. Hardin JA, Sherr DH, DeMaria M, Lopez PA. A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation. J Immunol Methods 1992; 154: 99-107.
24. Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L et al A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 1992; 101 (Part 4): 773-784.
25. Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS et al. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 2005; 105: 1237-1245.
26. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-133.
27. Stadtman ER. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radic Biol Med 1990; 9: 315-325.
28. Block G, Henson DE, Levine M. Vitamin C: A new look. Ann Intern Med 1991; 114: 909-910.
29. Besselink GA, van Engelenburg FA, Ebbing IG, Hilarius PM, de Korte D, Verhoeven AJ. Additive effects of dipyridamole and trolox in protecting human red cells during photodynamic treatment. Vox Sang 2003; 85: 25-30.
30. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-597.
31. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004; 11: 737-746.
32. Bailey HH. L-S,R-Buthionine sulfoximine: Historical development and clinical issues. Chem Biol Interact 1998; 111-112: 239-254.
33. Cross JV, Deak JC, Rich EA, Qian Y, Lewis M, Parrott LA et al. Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem 1999; 274: 31150-31154.
34. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A, Fardel O. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 2001; 61: 1387-1391.
35. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998; 92: 1497-1504.
36. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004; 101: 4578-4583.
37. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002; 21: 57-63.
38. Sakurai T, Kojima C, Kobayashi Y, Hirano S, Sakurai MH, Waalkes MP et al. Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). Br J Pharmacol 2006; 149: 888-897.
39. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 2004; 198: 458-467.
40. Dopp E, Hartmann LM, von Recklinghausen U, Florea AM, Rabieh S, Zimmermann U et al. Forced uptake of trivalent and pentavalent methylated and inorganic arsenic and its cyto-/genotoxicity in fibroblasts and hepatoma cells. Toxicol Sci 2005; 87: 46-56.